Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Hormone. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States



Survival: 34.7 months
   
Toxicity Grade: 5
   
Treatments: Hormone
   
Drugs:
Country: United States
   
City/State/Province: San Francisco, CA
   
Hospital: UCSF Helen Diller Family Comprehensive Cancer Center
   
Journal: Link
   
Date: 2/2015

Description:
Patients:
This phase 3 study involved chemotherapy-na´ve metastatic castration-resistant prostate cancer patients who were separated into two treatment groups. Group A consisted of 546 patients with a median age of 71 years. Group B had 542 patients with a median age of 70 years.

Treatment:
Patients in group A received hormone therapy with prednisone abiraterone acetate.

Patients in group B received hormone therapy with prednisone and a placebo.

Toxicities:
Cardiac adverse events that caused death were reported for group A. Grade 3 fluid retention/swelling and grade 4 liver toxicity were also reported.

Cardiac adverse events that caused death were reported for group B. Grade 3 fluid retention/swelling and grade 4 liver toxicity were also reported.

Results:
The median overall survival for groups A and B was 34.7 and 30.3 months, respectively.

Support:
This study was supported by Janssen Research & Development and many of the authors have received funding from several pharmaceutical companies.

Correspondence: Dr. Charles J Ryan; email: ryanc@medicine.ucsf.edu

E-mail to a Friend Email Physician More Information